Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

Haemophilia

Volumn 21, Issue 6, 2015, Pages 784-790

  Martinowitz, U ^a   Lissitchkov, T ^b   Lubetsky, A ^a   Jotov, G ^b   Barazani Brutman, T ^a   Voigt, C ^c   Jacobs, I ^c   Wuerfel, T ^d   Santagostino, E ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b SHAT Yoan Pavel   (Bulgaria)

^c CSL BEHRING   (United States)

^d CSL BEHRING GMBH   (Germany)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Factor IX; Haemophilia B; Haemostasis; Pharmacokinetics; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9; ALBUMINOID; HYBRID PROTEIN;

ADOLESCENT; ADULT; ANNUALIZED SPONTANEOUS BLEEDING RATE; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; BULGARIA; CLINICAL ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEMOPHILIA B; HEMOSTASIS; HUMAN; INCIDENCE; ISRAEL; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; TREATMENT DURATION; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; GENETICS; HEMORRHAGE; MIDDLE AGED; PATHOPHYSIOLOGY; SAFETY; YOUNG ADULT;

ADOLESCENT; ADULT; ALBUMINS; FACTOR IX; HEMOPHILIA B; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SAFETY; YOUNG ADULT;

EID: 84946493489     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12721     Document Type: Article

References (20)

1. National Hemophilia Foundation. MASAC recommendation #179: concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed February 25, 2015.
2. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
3. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998; 4: 413-7.
4. Funk M, Schmidt H, Escuriola-Ettinghausen C et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998; 77: 171-4.
5. De Moerloose P, Urbancik W, van den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-8.
6. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004; 10: 97-104.
7. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
8. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2012; 118: 2695-701.
9. Shapiro AD, Ragni MV, Valentino LA et al. Recombinant factor IX-Fc fusion protein (rFIX-Fc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
10. Schulte S. Half-life extension through albumin fusion technologies. Thromb Res 2009; 124: S6-8.
11. Knobe K, Berntorp E. New treatments in hemophilia: insights for the clinician. Ther Adv Hematol 2012; 3: 165-75.
12. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of Factor IX. Thromb Haemost 2009; 102: 634-44.
13. Nolte MW, Nichols TC, Mueller-Cohrs J et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs. J Thromb Haemost 2012; 10: 1591-9.
14. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
15. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; on behalf of International Prophylaxis Study Group (IPSG) Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
16. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10: 689-97.
17. European Medicines Agency. Committee for medicinal products for human use (CHMP), guideline in the clinical investigation of recombinant and human plasma-derived factor IX products. EMEA 2009CHMP/BPWP/144552/2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003634.pdf. Accessed February 25, 2015.
18. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
19. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res 2013; 131(Suppl. 2): S11-4.
20. Benefix Package Insert. 2011. Available at http://labeling.pfizer.com/showlabeling.aspx?id=492. Accessed August 2, 2012.